CAMP4 Analyst Highlights Rare Disease Platform Potential
CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts ...
Camp4 gains after earning bullish views on Street
Camp4 Therapeutics (CAMP) stock gains after J.P. Morgan and Piper Sandler launched its coverage with Overweight ...
Fintel on MSN8d
Leerink Partners Initiates Coverage of Camp4 Therapeutics (CAMP) with Outperform Recommendation
Fintel reports that on November 5, 2024, Leerink Partners initiated coverage of Camp4 Therapeutics (NasdaqGM:CAMP) with a ...
Camp4 Therapeutics initiated with an Overweight at Piper Sandler
Piper Sandler initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $18 price target The company is is pioneering ...
Investing8d
Piper Sandler optimistic on CAMP4 stock, cites potential in pioneering RNA technology
On Tuesday, Piper Sandler began coverage of CAMP4 Therapeutics Corp (NASDAQ:CAMP) stock with an Overweight rating and a price target of $18.00. The firm highlighted CAMP4's innovative work in the ...
Camp4 Therapeutics initiated with an Outperform at Leerink
Leerink initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating and $17 price target The firm believes CMP-CPS-001, the lead ...
Investing8d
William Blair upbeat on CAMP4 shares with Outperform rating
Tuesday, William Blair initiated coverage on CAMP4 Therapeutics Corp (NASDAQ: CAMP) shares with an Outperform rating and a fair value estimate of $27.43 per share. The firm recognized CAMP4's ...
Investing8d
Piper Sandler optimistic on CAMP4 stock, cites potential in pioneering RNA technology
On Tuesday, Piper Sandler began coverage of CAMP4 Therapeutics Corp (NASDAQ:CAMP) stock with an Overweight rating and a price target of $18.00. The firm highlighted CAMP4's innovative work in the ...
Nasdaq8d
Camp4 Therapeutics initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $23 price target The firm says its bullish thesis is based on Camp4’s ASO RNA Actuator Platform ...